Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug TB006 aims to ease movement problems in Parkinson's

NCT ID NCT06773962

Disease control Sponsor: TrueBinding, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2a trial tests whether the drug TB006 can safely improve motor function in people with early-stage Parkinson's disease. About 62 participants will receive either TB006 or a placebo by IV infusion. The study is double-blind, meaning neither patients nor doctors know who gets the real drug. Researchers will measure changes in movement and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TB006 (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment to improve motor function in early-stage Parkinson's disease.
What could go wrong
This is a small, early-phase trial with only 62 participants. The drug may not improve symptoms or could cause side effects. Results may not apply to all Parkinson's patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 62 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants voluntarily agree to participate in this study and sign an Institutional Review Board (IRB)-approved informed consent form (ICF) prior to performing any of the screening procedures. Parkinson's Disease Related Criteria: 2. Diagnosis of Parkinson's disease (PD) with motor symptom improvement from levodopa, if applicable. 3. Less than 5 years from the initial PD diagnosis, at the time of ICF. 4. Early-stage PD, with mild symptoms based on standard clinical staging in OFF state. 5. Participants who are on immediate-release levodopa-carbidopa/benserazide. Other Health Related Criteria 6. No active cancer, unless in remission for ≥10 years without ongoing treatment, except fully removed basal cell carcinoma. 7. Free of significant health issues that might interfere with study participation. Other Criteria/Social Circumstances 8. Negative screening for illegal drugs (excluding cannabis), with willingness to abstain during the study and avoid cannabis or alcohol effects during visits. Exclusion Criteria: Parkinsons's Disease Related Criteria 1. History of sudden, unexpected PD medication OFF episodes. 2. Severe motor complications or disabling symptoms that may impact study involvement. Other Health Related Criteria 3. Any condition or health concern deemed a safety risk or likely to interfere with study results. 4. Severe psychiatric disorders, including psychosis or substance addiction. 5. Allergies or sensitivities to specific study-related treatments or substances. 6. Any prior history of a severe infusion reaction. Other Criteria/Social Circumstances 7. Pregnancy, breastfeeding, or plans for pregnancy or ova donation during or shortly after the study. 8. Recent use of investigational drugs or therapeutic antibodies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease (PD)

Contacts and locations

Locations

  • CenExel Rocky Mountain Clinical Research

    Englewood, Colorado, 80113, United States

  • Central Texas Neurology Consultants

    Round Rock, Texas, 78681, United States

  • Consultants in Neurology, Ltd

    Northbrook, Illinois, 60062, United States

  • Josephson Wallack Munshower Neurology - Southeast

    Indianapolis, Indiana, 46256, United States

  • NYU Langone Health

    Patchogue, New York, 11772, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida, 33486, United States

  • Parkinson's Research Centers of America - Long Island

    Commack, New York, 11725, United States

  • Parkinson's Research Centers of America - Orange County

    Aliso Viejo, California, 92656, United States

  • Parkinson's Research Centers of America - Palo Alto

    Palo Alto, California, 94301, United States

  • Quest Research Institute

    Farmington Hills, Michigan, 48334, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of South Florida Parkinson's and Movement Disorders Center

    Tampa, Florida, 33613, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.